# EDGAR Filing Document

**Accession Number:** 0001948604
**File Stem:** 0000905148-25-002815
**Filing Date:** 2025-8
**Character Count:** 14294
**Document Hash:** ef2f13db5bbf156a8506c953f39f4630
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000905148-25-002815.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0000905148-25-002815

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Neumora Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001885522
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 844367680
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94162
- **FILM NUMBER:** 251202746

**BUSINESS ADDRESS:**
- **STREET 1:** 260 ARSENAL PLACE, SUITE 1
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** (857) 760-0900

**MAIL ADDRESS:**
- **STREET 1:** 260 ARSENAL PLACE, SUITE 1
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RBNC Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210929
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** K2 HealthVentures Equity Trust LLC
- **CENTRAL INDEX KEY:** 0001948604

**ORGANIZATION NAME:**
- **EIN:** 842128131
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 855 BOYLSTON STREET
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 857-201-5983

**MAIL ADDRESS:**
- **STREET 1:** 855 BOYLSTON STREET
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

## Ex-1

#### EXHIBIT 1

#### JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Neumora Therapeutics, Inc., dated as of August 11, 2025, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

---

| | | |
|:---|:---|:---|
| Dated: August 11, 2025 |  |  |
|  | **K2 HEALTHVENTURES EQUITY TRUST LLC** | **K2 HEALTHVENTURES EQUITY TRUST LLC** |
|  | By: | /s/ Anup Arora |
|  | Name: | Anup Arora |
|  | Title: | Managing Member |
|  | **PARAG SHAH** | **PARAG SHAH** |
|  | By: | /s/ Parag Shah |
|  | **ANUP ARORA** | **ANUP ARORA** |
|  | By: | /s/ Anup Arora |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** Neumora Therapeutics, Inc.

**Title of Class of Securities:** Common Stock, par value $0.0001 per share

**CUSIP Number:** 640979100

**Date of Event Which Requires Filing of this Statement:** 05/09/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>K2 HealthVentures Equity Trust LLC | Names of Reporting Persons<br>K2 HealthVentures Equity Trust LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>11397310 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>11397310 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>11397310 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>11397310 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.6% | Percent of Class Represented by Amount in Row (9)<br>6.6% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

---

| 1. | Names of Reporting Persons<br>Parag Shah | Names of Reporting Persons<br>Parag Shah |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>11397310 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>11397310 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>11397310 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>11397310 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.6% | Percent of Class Represented by Amount in Row (9)<br>6.6% |
| 12. | Type of Reporting Person (See Instructions)<br>IN, HC | Type of Reporting Person (See Instructions)<br>IN, HC |

---

| 1. | Names of Reporting Persons<br>Anup Arora | Names of Reporting Persons<br>Anup Arora |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>11397310 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>11397310 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>11397310 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>11397310 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.6% | Percent of Class Represented by Amount in Row (9)<br>6.6% |
| 12. | Type of Reporting Person (See Instructions)<br>IN, HC | Type of Reporting Person (See Instructions)<br>IN, HC |

---

**Item 1(a). Name of Issuer:**
Neumora Therapeutics, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
260 Arsenal Place, Suite 1, Watertown, Massachusetts, 02472

**Item 2(a). Name of Person Filing:**
This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):

i.	K2 HealthVentures Equity Trust LLC ("K2HV Equity");
ii.	Parag Shah ("Mr. Shah"); and
iii.	Anup Arora ("Mr. Arora").

This Statement on Schedule 13G relates to shares of Common Stock K2HV Equity has the right to acquire within 60 days upon conversion of up to $10,000,000 of outstanding principal of the Issuer's outstanding debt obligations to K2HV Equity under a loan and security agreement the Issuer and K2HV Equity entered into on May 9, 2025, at a conversion price of the lesser of $0.8774 per share and the lowest effective price per share of the Issuer's next equity financing (the "Conversion Shares").  For purposes of this Schedule 13G, we have assumed a conversion price of $0.8774 per share, which results in the Reporting Persons beneficially owning approximately 11,397,310 shares of Common Stock

K2HV Equity is an investment vehicle for holding equity securities and may be deemed to directly beneficially own the shares of Common Stock that it has the right to acquire upon conversion of the Conversion Shares, as reported herein.  Mr. Shah and Mr. Arora serve as the managing members of K2HV Equity and, in such capacities, may be deemed to indirectly beneficially own the shares of Common Stock that K2HV Equity directly beneficially owns.

**Item 2(b). Address of Principal Business Office:**
The business address of each of the Reporting Persons is: 855 Boylston Street, 10th Floor, Boston, MA 02116.

**Item 2(c). Citizenship:**
K2HV Equity is a Delaware limited liability company.  Each of Mr. Shah and Mr. Arora is a citizen of the United States of America.

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**Item 2(e). CUSIP Number:**
640979100

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

As of May 9, 2025 and the date hereof, each of the Reporting Persons may be deemed the beneficial owner of 11,397,310 shares of Common Stock, which consist entirely of shares of Common Stock K2HV Equity has the right to acquire upon conversion of the Conversion Shares.

**(b) Percent of class:**

As of May 9, 2025 and the date hereof, each of the Reporting Persons may be deemed the beneficial owner of approximately 6.6% of the shares of Common Stock outstanding.
The percentage set forth herein is calculated based on the sum of (i) 161,747,922 shares of Common Stock outstanding as of May 5, 2025 and 161,945,427 shares of Common Stock outstanding as of August 1, 2025, as reported in the Issuer's quarterly reports on Form 10-Q, filed with the Securities and Exchange Commission on May 12, 2025 and August 6, 2025, respectively, and (ii) 11,397,310 shares of Common Stock that are issuable to K2HV Equity within 60 days upon conversion of the Conversion Shares, which Conversion Shares have been added to the total shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

0

**(ii) Shared power to vote or to direct the vote:**

11,397,310

**(iii) Sole power to dispose or to direct the disposition of:**

0

**(iv) Shared power to dispose or to direct the disposition of:**

11,397,310

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**K2 HealthVentures Equity Trust LLC**

**Date:** 08/11/2025

**By:** /s/ Anup Arora

**Name & Title:** Anup Arora, Managing Member

**Parag Shah**

**Date:** 08/11/2025

**By:** /s/ Parag Shah

**Name & Title:** Parag Shah

**Anup Arora**

**Date:** 08/11/2025

**By:** /s/ Anup Arora

**Name & Title:** Anup Arora